Meropenem
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1996
- First approval year
- 1996
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Meropenem
- Molecular weight
- 383.47
- Structure (SMILES)
- C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12
- meropenem
- Meropenem
- meropenem component of vabomere
- Meropenem component of vabomere
- merrem
- Merrem
- daptomycin meropenem
- ici 194 660
- ICI 194,660
- ici 194660
- ICI-194660
- IV meropenem
- meronem
- Meronem
- meropenem
- Meropenem
- MEROPENEM
- meropenem (active comparator)
- Meropenem (as trihydrate)
- meropenem [INN]
- MEROPENEM [MI]
- Meropenem [WHO-DD]
- Meropenem 1000 mg
- Meropenem 3g IV
- Meropenem 4g IV
- meropenem anhydrous
- Meropenem anhydrous
- meropenem as trihydrate
- Meropenem for injection
- Meropenem for Injection
- meropenem hydrate
And 19 more, listed on the interactive page.
- ATC classification codes
- J01DH02
Sources for recorded values
- CAS registry numbers
- 96036-03-2
- ChEMBL ID
- CHEMBL127
- InChIKey
- DMJNNHOOLUXYBV-PQTSNVLCSA-N
- FDA ingredient codes (UNII)
- YOP6PX0BAO
- 441130
- 40466974
- 29561
- 1546029
- Applicant
- PFIZER
- Approval date
- 21 Jun 1996
- Application number
- NDA050706
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- meropenem
- Type
- Synthetic organic
- Drug name stem
- -penem
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P02918
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P02919
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P08506
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P0AD65
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P0AD68
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P0AEB2
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
- Protein identifier
- P24228
Open Targets mechanisms
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Action type
- Inhibitor
- Target
- Bacterial penicillin-binding protein
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- dacB
- Protein identifier
- P24228
- Organism
- Escherichia coli (strain K12)
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Intraabdominal Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D059413
- Condition
- Meningitis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000584
- Subject identifier
- D008581
- Condition
- Bacterial Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition
- Bacteremia
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003033
- Subject identifier
- D016470
- Condition
- Osteomyelitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003102
- Subject identifier
- D010019
- Condition
- Urinary Tract Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003103
- Subject identifier
- D014552
- Condition
- Pneumonia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Lung Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003818
- Subject identifier
- D008171
- Condition
- Communicable Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005741
- Subject identifier
- D003141
- Condition
- Shock, Septic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0006834
- Subject identifier
- D012772
- Condition
- Appendicitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007149
- Subject identifier
- D001064
- Condition
- Respiratory Insufficiency
- Highest recorded phase
- 1
- Condition identifier
- EFO:0009686
- Subject identifier
- D012131
- Condition
- Tuberculosis, Pulmonary
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000049
- Subject identifier
- D014397
- Condition
- Pancreatitis
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000652
- Subject identifier
- D010195
- Condition
- Meningitis, Bacterial
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000831
- Subject identifier
- D016920
- Condition
- Pyelonephritis
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001141
- Subject identifier
- D011704
- Condition
- Pneumonia, Bacterial
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001272
- Subject identifier
- D018410
- Condition
- Enterobacteriaceae Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001313
- Subject identifier
- D004756
- Condition
- Pneumonia, Ventilator-Associated
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001865
- Subject identifier
- D053717
- Condition
- Neonatal Sepsis
- Highest recorded phase
- 3
- Condition identifier
- HP:0040187
- Subject identifier
- D000071074
- Condition
- Sepsis
- Highest recorded phase
- 3
- Condition identifier
- HP:0100806
- Subject identifier
- D018805
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001187
- Subject identifier
- D001749
- Condition
- Mental Disorders
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002025
- Subject identifier
- D001523
- Condition
- Tuberculosis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0018076
- Subject identifier
- D014376
And 3 more, listed on the interactive page.
- Condition identifier
- EFO_0000540
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000584
- Condition identifier
- EFO_0000771
- Condition identifier
- EFO_0003033
- Condition identifier
- EFO_0003102
- Condition identifier
- EFO_0003103
- Condition identifier
- EFO_0003106
- Condition identifier
- EFO_0005140
- Condition identifier
- EFO_0005741
- Highest recorded phase
- 2
- Condition identifier
- EFO_0006834
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007149
- Condition identifier
- EFO_0009686
- Condition identifier
- EFO_1000652
- Condition identifier
- EFO_1000831
- Condition identifier
- EFO_1001141
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001313
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001345
- Condition identifier
- EFO_1001865
- Condition identifier
- EFO_1001865
- Highest recorded phase
- 4
- Condition identifier
- HP_0000010
- Condition identifier
- HP_0011947
- Condition identifier
- HP_0011947
- Highest recorded phase
- 4
- Condition identifier
- HP_0040187
- Highest recorded phase
- 3
And 27 more, listed on the interactive page.
- Event
- acinetobacter infection
- Reports
- 25
- Reporting signal score
- 86.2112
- Event
- acute generalised exanthematous pustulosis
- Reports
- 63
- Reporting signal score
- 117.519
- Event
- acute kidney injury
- Reports
- 159
- Reporting signal score
- 83.5029
- Event
- agranulocytosis
- Reports
- 76
- Reporting signal score
- 102.406
- Event
- bronchopulmonary aspergillosis
- Reports
- 41
- Reporting signal score
- 86.0547
- Event
- c-reactive protein increased
- Reports
- 82
- Reporting signal score
- 85.2358
- Event
- candida infection
- Reports
- 88
- Reporting signal score
- 195.271
- Event
- cholestasis
- Reports
- 67
- Reporting signal score
- 80.5341
- Event
- clostridium difficile colitis
- Reports
- 80
- Reporting signal score
- 171.015
- Event
- clostridium difficile infection
- Reports
- 82
- Reporting signal score
- 144.102
- Event
- clostridium test positive
- Reports
- 21
- Reporting signal score
- 54.9384
- Event
- drug interaction
- Reports
- 169
- Reporting signal score
- 65.661
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 265
- Reporting signal score
- 592.352
- Event
- drug resistance
- Reports
- 158
- Reporting signal score
- 302.378
- Event
- enterococcal infection
- Reports
- 39
- Reporting signal score
- 92.1639
- Event
- eosinophilia
- Reports
- 139
- Reporting signal score
- 281.582
- Event
- fatigue
- Reports
- 28
- Reporting signal score
- 92.9683
- Event
- fungaemia
- Reports
- 20
- Reporting signal score
- 57.8336
- Event
- headache
- Reports
- 37
- Reporting signal score
- 54.8032
- Event
- hepatic cytolysis
- Reports
- 29
- Reporting signal score
- 61.8841
- Event
- hepatic function abnormal
- Reports
- 85
- Reporting signal score
- 88.402
- Event
- hepatitis
- Reports
- 63
- Reporting signal score
- 63.4126
- Event
- herpes simplex oesophagitis
- Reports
- 18
- Reporting signal score
- 81.5657
- Event
- inflammatory marker increased
- Reports
- 30
- Reporting signal score
- 65.8195
- Event
- klebsiella infection
- Reports
- 42
- Reporting signal score
- 100.081
And 18 more, listed on the interactive page.
- NCT00050401
- NCT01597973
- NCT01808092
- NCT03032380
- NCT00307099
- NCT00410527
- NCT04816968
- NCT05226923
- NCT00752219
- NCT01147640
- NCT01381562
- NCT01445665
- NCT01445678
- NCT01499290
- NCT01500239
- NCT01726023
- NCT01944319
- NCT02142751
- NCT02176122
- NCT02437045
- NCT02475733
- NCT03217136
- NCT03830333
- NCT04876430
- NCT05340530
And 33 more, listed on the interactive page.
- Dose
- 500 mg
- Route
- Intravenous
- How often
- Every 8 hours
- Infused over 15 to 30 minutes
- Or bolus injection over 3 to 5 minutes
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 3
- Polar surface area
- 110.18
- Calculated partition coefficient (ALogP)
- -0.31
- Calculated partition coefficient (XLogP)
- -2.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 26
- Molecular formula
- C17H25N3O5S
- Monoisotopic mass
- 383.15149208
- Natural product
- Yes
- 72078-081
- 81962-002
- Recorded assays
- 8,335
- Active assays
- 123
- Confirmatory
- Other
- Screening
- Anti-Bacterial Agents
Related records
Trials (293)
- A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants
- A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection
- A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337
- A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients
- A Clinical Trial to Evaluate the Safety and Efficacy of "AG1904" in Acute Bronchitis
- A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470
- A Gene by Medication Interaction to the Acute Effects of Alcohol
- A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
- A Phase I SAD/MAD and Liver Effect Study of Vitalangio in Venous Thromboembolism Patients .
- A Pilot Study for Optimizing Meropenem Administration in the ICU
- A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis
- A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study
- A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
- A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients
- A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)
- A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia
- A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)
- A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)
- A Study of Meropenem Standard 30 Minute Infusion Versus Prolonged 3 Hour Infusion in Intensive Care Unit (ICU) Patients
- A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
Approved for (6)
- Bacterial infectious disease
- Bacterial infectious disease with sepsis
- Bacterial meningitis
- Infectious meningitis
- Meningitis
- Urinary tract infection
In development for (17)
- Acute pancreatitis Phase 1
- Appendicitis Phase 2
- Bacterial pneumonia Phase 3
- Gram-negative bacterial infections Phase 1
- Hematopoietic and lymphoid cell neoplasm Phase 2
- Infectious disease Phase 2
- Lung disorder Phase 3
- Neonatal sepsis Phase 3
- Osteomyelitis Early phase 1
- Pneumonia Phase 3
- Psychiatric disorder Phase 3
- Pulmonary tuberculosis Phase 2
- Pyelonephritis Phase 3
- Respiratory failure Phase 1
- Toxic shock syndrome Phase 3
- Tuberculosis Phase 2
- Urinary bladder cancer Phase 3
Other linked conditions (2)
- Alcoholic hepatitis
- Immune system disorder